Literature DB >> 23420397

Comparison of microRNA expression levels between initial and recurrent glioblastoma specimens.

Aysegül Ilhan-Mutlu1, Adelheid Wöhrer, Anna Sophie Berghoff, Georg Widhalm, Christine Marosi, Ludwig Wagner, Matthias Preusser.   

Abstract

Glioblastoma is the most frequent primary brain tumour in adults. Recent therapeutic advances increased patient's survival, but tumour recurrence inevitably occurs. The pathobiological mechanisms involved in glioblastoma recurrence are still unclear. MicroRNAs are small RNAs proposed o have important roles for cancer including proliferation, aggressiveness and metastases development. There exist only few data on the involvement of microRNAs in glioblastoma recurrence. We selected the following 7 microRNAs with potential relevance for glioblastoma pathobiology by means of a comprehensive literature search: microRNA-10b, microRNA-21, microRNA-181b, microRNA-181c, microRNA-195, microRNA-221 and microRNA-222. We further selected 15 primary glioblastoma patients, of whom formalin fixed and paraffin embedded tissue (FFPE) of the initial and recurrence surgery were available. All patients had received first line treatment consisting of postoperative combined radiochemotherapy with temozolomide (n = 15). Non-neoplastic brain tissue samples from 3 patients with temporal lobe epilepsy served as control. The expression of the microRNAs were analysed by RT-qPCR. These were correlated with each other and with clinical parameters. All microRNAs showed detectable levels of expressions in glioblastoma group, whereas microRNA-10b was not detectable in epilepsy patients. MicroRNAs except microRNA-21 showed significantly higher levels in epilepsy patients when compared to the levels of first resection of glioblastoma. Comparison of microRNA levels between first and second resections revealed no significant change. Cox regression analyses showed no significant association of microRNA expression levels in the tumor tissue with progression free survival times. Expression levels of microRNA-10b, microRNA-21, microRNA-181b, microRNA-181c, microRNA-195, microRNA-221 and microRNA-222 do not differ significantly between initial and recurrent glioblastoma.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23420397     DOI: 10.1007/s11060-013-1078-6

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  51 in total

1.  Downregulation of miR-21 inhibits EGFR pathway and suppresses the growth of human glioblastoma cells independent of PTEN status.

Authors:  Xuan Zhou; Yu Ren; Lynette Moore; Mei Mei; Yongping You; Peng Xu; Baoli Wang; Guangxiu Wang; Zhifan Jia; Peiyu Pu; Wei Zhang; Chunsheng Kang
Journal:  Lab Invest       Date:  2010-01-04       Impact factor: 5.662

2.  MicroRNA-195 plays a tumor-suppressor role in human glioblastoma cells by targeting signaling pathways involved in cellular proliferation and invasion.

Authors:  Qian-Qian Zhang; Hui Xu; Mian-Bo Huang; Li-Ming Ma; Qiao-Juan Huang; Qing Yao; Hui Zhou; Liang-Hu Qu
Journal:  Neuro Oncol       Date:  2012-01-04       Impact factor: 12.300

3.  MiR-21 modulates hTERT through a STAT3-dependent manner on glioblastoma cell growth.

Authors:  Ying-Yi Wang; Guan Sun; Hui Luo; Xie-Feng Wang; Feng-Ming Lan; Xiao Yue; Lin-Shan Fu; Pei-Yu Pu; Chun-Sheng Kang; Ning Liu; Yong-Ping You
Journal:  CNS Neurosci Ther       Date:  2012-06-18       Impact factor: 5.243

4.  MicroRNA-21 inhibitor sensitizes human glioblastoma cells U251 (PTEN-mutant) and LN229 (PTEN-wild type) to taxol.

Authors:  Yu Ren; Xuan Zhou; Mei Mei; Xu-Bo Yuan; Lei Han; Guang-Xiu Wang; Zhi-Fan Jia; Peng Xu; Pei-Yu Pu; Chun-Sheng Kang
Journal:  BMC Cancer       Date:  2010-01-31       Impact factor: 4.430

5.  Effect of miR-21 and miR-30b/c on TRAIL-induced apoptosis in glioma cells.

Authors:  C Quintavalle; E Donnarumma; M Iaboni; G Roscigno; M Garofalo; G Romano; D Fiore; P De Marinis; C M Croce; G Condorelli
Journal:  Oncogene       Date:  2012-09-10       Impact factor: 9.867

6.  Co-suppression of miR-221/222 cluster suppresses human glioma cell growth by targeting p27kip1 in vitro and in vivo.

Authors:  Chunzhi Zhang; Chunsheng Kang; Yongping You; Peiyu Pu; Weidong Yang; Peng Zhao; Guangxiu Wang; Anling Zhang; Zhifan Jia; Lei Han; Hao Jiang
Journal:  Int J Oncol       Date:  2009-06       Impact factor: 5.650

7.  Regulation of p27Kip1 by miRNA 221/222 in glioblastoma.

Authors:  Jana K Gillies; Ian A J Lorimer
Journal:  Cell Cycle       Date:  2007-05-31       Impact factor: 4.534

8.  PDGF-B-mediated downregulation of miR-21: new insights into PDGF signaling in glioblastoma.

Authors:  Pedro M Costa; Ana L Cardoso; Luis F Pereira de Almeida; Jeffrey N Bruce; Peter Canoll; Maria C Pedroso de Lima
Journal:  Hum Mol Genet       Date:  2012-08-24       Impact factor: 6.150

9.  MicroRNA-21 down-regulates the expression of tumor suppressor PDCD4 in human glioblastoma cell T98G.

Authors:  Yang Chen; Wei Liu; Tengfei Chao; Yu Zhang; Xingqi Yan; Yanhua Gong; Boqin Qiang; Jiangang Yuan; Maosheng Sun; Xiaozhong Peng
Journal:  Cancer Lett       Date:  2008-11-13       Impact factor: 8.679

10.  Prediction of Associations between microRNAs and Gene Expression in Glioma Biology.

Authors:  Stefan Wuchty; Dolores Arjona; Aiguo Li; Yuri Kotliarov; Jennifer Walling; Susie Ahn; Alice Zhang; Dragan Maric; Rachel Anolik; Jean Claude Zenklusen; Howard A Fine
Journal:  PLoS One       Date:  2011-02-16       Impact factor: 3.240

View more
  8 in total

1.  Expression profiling of angiogenesis-related genes in brain metastases of lung cancer and melanoma.

Authors:  Aysegül Ilhan-Mutlu; Christian Siehs; Anna Sophie Berghoff; Gerda Ricken; Georg Widhalm; Ludwig Wagner; Matthias Preusser
Journal:  Tumour Biol       Date:  2015-08-16

2.  miR-181 subunits enhance the chemosensitivity of temozolomide by Rap1B-mediated cytoskeleton remodeling in glioblastoma cells.

Authors:  Xiaoling She; Zhibin Yu; Yulong Cui; Qianqian Lei; Zeyou Wang; Gang Xu; Zhaohui Luo; Guiyuan Li; Minghua Wu
Journal:  Med Oncol       Date:  2014-02-27       Impact factor: 3.064

Review 3.  A comprehensive profile of recurrent glioblastoma.

Authors:  B Campos; L R Olsen; T Urup; H S Poulsen
Journal:  Oncogene       Date:  2016-04-04       Impact factor: 9.867

Review 4.  MicroRNA expression signatures determine prognosis and survival in glioblastoma multiforme--a systematic overview.

Authors:  Michael Henriksen; Kasper Bendix Johnsen; Hjalte Holm Andersen; Linda Pilgaard; Meg Duroux
Journal:  Mol Neurobiol       Date:  2014-03-12       Impact factor: 5.590

5.  Dynamic expression of 11 miRNAs in 83 consecutive primary and corresponding recurrent glioblastoma: correlation to treatment, time to recurrence, overall survival and MGMT methylation status.

Authors:  Bostjan Matos; Emanuela Bostjancic; Alenka Matjasic; Mara Popovic; Damjan Glavac
Journal:  Radiol Oncol       Date:  2018-11-26       Impact factor: 2.991

Review 6.  miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review.

Authors:  Maria Teresa Di Martino; Mariamena Arbitrio; Daniele Caracciolo; Alessia Cordua; Onofrio Cuomo; Katia Grillone; Caterina Riillo; Giulio Caridà; Francesca Scionti; Caterina Labanca; Caterina Romeo; Maria Anna Siciliano; Maria D'Apolito; Cristina Napoli; Martina Montesano; Valentina Farenza; Valentina Uppolo; Michele Tafuni; Federica Falcone; Giuseppe D'Aquino; Natale Daniele Calandruccio; Francesco Luciano; Licia Pensabene; Pierosandro Tagliaferri; Pierfrancesco Tassone
Journal:  Mol Ther Nucleic Acids       Date:  2022-02-11       Impact factor: 8.886

7.  Prognostic role of microRNA-221 in various human malignant neoplasms: a meta-analysis of 20 related studies.

Authors:  Jie Yang; Jia-yi Zhang; Jing Chen; Yang Xu; Ning-hong Song; Chang-jun Yin
Journal:  PLoS One       Date:  2014-01-27       Impact factor: 3.240

8.  Prognostic value of miR-21 in gliomas: comprehensive study based on meta-analysis and TCGA dataset validation.

Authors:  Guli Jiang; Jing Mu; Xing Liu; Xiangni Peng; Feiya Zhong; Wenliang Yuan; Fang Deng; Xiaoning Peng; Sihua Peng; Xiaomin Zeng
Journal:  Sci Rep       Date:  2020-03-06       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.